Alpha 2.0
Login Register
» Authors » Fabian Model

Fabian Model

Explore the profile of Fabian Model including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 1441
Followers 0
Related Specialties
Neurology
Biochemistry
Oncology
Top 10 Co-Authors
Ludwig Kappos
Stephen L Hauser
Catherine Lofton-Day
Qing Wang
Marianna Manfrini
Harold Koendgen
Shibeshih Belachew
Volker Liebenberg
Corrado Bernasconi
Bela Molnar
Published In
Cancer Res
Clin Chem
Neurol Neuroimmunol Neuroinflamm
J Cent Nerv Syst Dis
Nucleic Acids Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments
Muros-Le Rouzic E, Heer Y, Yiu S, Tozzi V, Braune S, van Hovell P, et al.
J Cent Nerv Syst Dis . 2024 Sep; 16:11795735241260563. PMID: 39290861
Background: Clinical trials comparing the efficacy of ocrelizumab (OCR) with other disease-modifying therapies (DMTs) other than interferon (IFN) β-1a in relapsing multiple sclerosis (RMS) are lacking. Objectives: To compare the...
2.
Estimating drug concentration-response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes
Yiu S, Wang Q, Mercier F, Manfrini M, Koendgen H, Kletzl H, et al.
Stat Methods Med Res . 2023 Nov; 32(12):2440-2454. PMID: 37964549
In clinical development, it is useful to characterize the causal relationship between individual drug concentrations and clinical outcomes in large phase III trials of new therapeutic agents because it can...
3.
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
Bar-Or A, Thanei G, Harp C, Bernasconi C, Bonati U, Cross A, et al.
EBioMedicine . 2023 Jun; 93:104662. PMID: 37354600
Background: Neurofilament light chain (NfL), a neuronal cytoskeletal protein that is released upon neuroaxonal injury, is associated with multiple sclerosis (MS) relapsing activity and has demonstrated some prognostic ability for...
4.
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
Hauser S, Bar-Or A, Weber M, Kletzl H, Gunther A, Manfrini M, et al.
Neurol Neuroimmunol Neuroinflamm . 2023 Feb; 10(2). PMID: 36792367
Background And Objectives: Ocrelizumab improved clinical and MRI measures of disease activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses demonstrated a correlation between the...
5.
Recurrent disability progression endpoints in multiple sclerosis clinical trials
Buhler A, Wolbers M, Model F, Wang Q, Belachew S, Manfrini M, et al.
Mult Scler . 2022 Sep; 29(1):130-139. PMID: 36177953
Background: The current standard endpoint to assess disability accumulation in multiple sclerosis (MS) clinical trials is the time to the first confirmed disability progression, which excludes subsequent progression events. Including...
6.
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
Butzkueven H, Spelman T, Horakova D, Hughes S, Solaro C, Izquierdo G, et al.
Eur J Neurol . 2021 Mar; 29(4):1082-1090. PMID: 33724638
Background And Purpose: Reaching Expanded Disability Status Scale (EDSS) ≥7.0 represents the requirement for a wheelchair. Here we (i) assess the effect of ocrelizumab on time to EDSS ≥7.0 over...
7.
Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO
Gibiansky E, Petry C, Mercier F, Gunther A, Herman A, Kappos L, et al.
Br J Clin Pharmacol . 2020 Nov; 87(6):2511-2520. PMID: 33202059
Aims: Ocrelizumab is a humanized monoclonal antibody that selectively targets CD20-positive B cells and is indicated for treatment of patients with relapsing forms of multiple sclerosis (RMS) or primary progressive...
8.
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
Hauser S, Kappos L, Arnold D, Bar-Or A, Brochet B, Naismith R, et al.
Neurology . 2020 Jul; 95(13):e1854-e1867. PMID: 32690791
Objective: To assess over 3 years of follow-up the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension...
9.
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
Kappos L, Wolinsky J, Giovannoni G, Arnold D, Wang Q, Bernasconi C, et al.
JAMA Neurol . 2020 Jun; 77(9):1132-1140. PMID: 32511687
Importance: Accumulation of disability in multiple sclerosis may occur as relapse-associated worsening (RAW) or steady progression independent of relapse activity (PIRA), with PIRA regarded as a feature of primary and...
10.
Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach
Donohue M, Model F, Delmar P, Volye N, Liu-Seifert H, Rafii M, et al.
Alzheimers Dement . 2020 Apr; 16(5):797-803. PMID: 32270600
In clinical trials in populations with mild cognitive impairment, it is common for participants to initiate concurrent symptomatic medications for Alzheimer's disease after randomization to the experimental therapy. One strategy...